| abstract |
The invention relates to compounds of the formula (I)n nwherein nn nis 0, 1 or 2; nG nis CH 2 or CHR 3 ; nR 1 nis H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; nR 2 R 3 and R 4 nare, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; nA nis phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF 3 ; nE nis NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; nAr nis a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; n nand physiologically tolerated acid addition salts thereof. n The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand. |